预约演示
更新于：2025-06-30
Dexpanthenol
右泛醇
更新于：2025-06-30
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1959-03-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H19NO4 |
InChIKeySNPLKNRPJHDVJA-ZETCQYMHSA-N |
CAS号81-13-0 |
关联
33
项与 右泛醇 相关的临床试验NCT06822608
Evaluation of a Fixed Combination of Dexpanthenol and Hyaluronic Acid Preservative-free Eye Drops on Corneal Epithelialization After Trans Epithelial PRK: a Prospective, Contralateral, Randomized, Double-blind, Placebo-controlled Trial
IRCT20240809062706N2
The effect of topical dexpanthenol cream on the prevention of striae in primigravida women: A double-blind randomized controlled trial
IRCT20220516054879N6
A comparative study of the effects of Hypericum Perforatum and Dexpanthenol topical cream on the healing process of scar caused by neck surgeries
100 项与 右泛醇 相关的临床结果
登录后查看更多信息
100 项与 右泛醇 相关的转化医学
登录后查看更多信息
100 项与 右泛醇 相关的专利（医药）
登录后查看更多信息
1,243
项与 右泛醇 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
The pantothenic acid derivative dexpanthenol ameliorated doxorubicin-induced neurotoxicity via regulating AKT/CREB/BDNF and AKT/NRF2 signaling pathways
Article
作者: Savran, Mehtap ; Ozmen, Ozlem ; Imeci, Orhan ; Asci, Halil ; Unlu, Melike Dogan
BACKGROUND:
Doxorubicin (Dox)-induced neurotoxicity is a well-documented side effect of chemotherapy. Dexpanthenol (Dex), an analog of vitamin B5, has shown protective properties. This study aimed to explore the molecular mechanisms by which Dex mitigates Dox-induced neurotoxicity, particularly through the protein kinase B (AKT)/cyclic AMP-response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) pathway and nuclear factor erythroid 2-related factor 2 (NRF2) signaling.
METHODS AND RESULTS:
The experiment was conducted using four groups: control, Dex, Dox, and Dox + Dex, comprising a total of 32 female Wistar Albino rats. After two weeks of treatment, the rats were euthanized, and brain and cerebellum tissues were collected for analysis. Biochemical analysis was performed spectrophotometrically to assess oxidative stress parameters, while histological and immunostaining analyses focused on nuclear factor kappa B (NF-κB) and inducible nitric oxide synthase (iNOS) immunoexpressions. Genetic analysis of AKT, CREB, BDNF, and NRF2 gene expressions was conducted using real-time polymerase chain reaction. Histopathological evaluation of the Dox group revealed hyperemia, microhemorrhage, neuronal damage, and neuronophagia. Additionally, an increase in caspase-3, tumor necrosis factor-alpha, NF-κB, and iNOS immunoexpressions were observed, along with elevated total oxidant status and oxidative stress index. A decrease in AKT, CREB, BDNF, and NRF2 gene expressions accompanied these changes. Dex treatment significantly reversed these pathological findings, effectively protecting the brain from Dox-induced neuronal damage.
CONCLUSION:
In conclusion, Dex may provide neuroprotection in female rats with Dox-induced neurotoxicity by activating the CREB/BDNF pathway and reducing oxidative stress through AKT-mediated NRF2 synthesis. Further detailed studies exploring additional pathways are required to incorporate Dex into cancer treatment protocols and minimize side effects.
2025-08-01Current Drug Delivery
Fluconazole-loaded Hyaluronic Acid-modified Transfersomal Hydrogels Containing D-panthenol for Ocular Delivery in Fungal Keratitis Management
Article
作者: Das, Biswarup ; Mallick, Subrata ; Nayak, Amit Kumar
Background::
Fungal keratitis (mycotic keratitis) is an eye infection in which the cornea is
infected by fungi and such fungal keratitis management can be effectively possible by ocular administration
of antifungal drugs.
Objective::
The main objectives of the present research were to develop and evaluate fluconazoleloaded
transfersomal hydrogels for ocular delivery in the effective management of fungal keratitis.
Methods::
A 23 factorial design-based approach was used for statistical optimization, where (A) the
ratio of lipid to edge activators, (B) the amount of hyaluronic acid (% HA), and (C) the ratio of edge
activators (sodium deoxycholate to Span 80) were taken as three factors. The average vesicle diameter
(Z, nm) of transfersomes was taken as a response. Further, fluconazole-loaded transfersomes
(FTO) were incorporated into 1% Carbopol 940-based hydrogel (OF1) and 2% HMPC K4M-based
hydrogel (OF2) containing D-panthenol (5% w/w).
Results::
The optimal variable setting for the optimized formulations of FTO was (A) = 9.15, (B) =
0.30%, and (C) = 3.00. FTO exhibited 66.39 nm Z, 0.247 polydispersity index, – 33.10 mV zeta potential,
and 65.38 ± 1.77 % DEE, and desirable elasticity. TEM image of FTO demonstrated a unilamellar
vesicular structure. The ex vivo ocular permeation of fluconazole from transfersomal hydrogels
was sustained over 24 h. All the transfersomal hydrogels showed good bioadhesion and excellent
antifungal activity with respect to the zone of inhibition against Candida albicans than Aspergillus
fumigates, in vitro. HET-CAM study results demonstrated that both the hydrogels were nonirritant
and safe for ocular. Short-term physical stability study suggested the stability of the developed
formulation.
Conclusion::
The current research demonstrated a new way to enhance the ocular penetration of fluconazole
via transfersomal hydrogel formulations for ocular delivery in the effective management of
fungal keratitis.
2025-07-01CORNEA
Effects of Dexpanthenol on Corneal Neovascularization and Inflammation on Rat Model
Article
作者: Tok, Levent ; Acer, Semra ; Celik, Omer ; Isleyen, Busra ; Tok, Ozlem
Purpose::
To evaluate the effect of subconjunctival injection of dexpanthenol on corneal neovascularization and inflammation in rats with induced chemical burns.
Methods::
This experimental study included 40 female albino Wistar rats. Chemical burns were induced in the right eye of all rats on the first day, and the left eye was used as a control. Rats were randomly divided into 5 groups. The no-treatment group (group 1) received no injections. Balanced salt solution injection in the sham group (group 2), dexpanthenol injection in the dexpanthenol group (group 3), bevacizumab injection in the bevacizumab group (group 4), and combined dexpanthenol and bevacizumab injection in the combined group (group 5) were administered subconjunctivally on day 7. The right corneas of all rats were photographed on days 7 and 14 to evaluate corneal neovascularization. The 2 corneal images were compared, and the differences were analyzed. All rats were euthanized, and the corneas were isolated. The levels of tumor necrosis factor-alpha (TNF-α), vascular endothelial growth factor-A, malondialdehyde (MDA), apoptosis, reduced glutathione (GSH), and total oxidant status were measured in rat corneas.
Results::
Dexpanthenol reduced corneal neovascularization, and the difference was significant compared with the no-treatment and sham groups (P < 0.05). No significant difference in corneal neovascularization was observed between the dexpanthenol and bevacizumab groups. Dexpanthenol had a significant positive effect on vascular endothelial growth factor-A, TNF-α, total oxidant status, MDA, and GSH levels compared with the sham group (P < 0.05).
Conclusions::
Dexpanthenol may help control corneal neovascularization and inflammation after chemical burns.
100 项与 右泛醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泛酸缺乏症 | 日本 | 1959-03-20 | |
| 维生素B缺乏症 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病足 | 临床3期 | 埃及 | 2011-07-01 | |
| 皮疹 | 临床3期 | 荷兰 | 2010-09-01 | |
| 肿瘤 | 临床3期 | 荷兰 | 2010-09-01 | |
| 烧伤 | 临床2期 | 法国 | 2007-09-01 | |
| 红斑 | 临床2期 | 法国 | 2007-09-01 | |
| 皮肤异常 | 临床2期 | 法国 | 2007-08-01 | |
| 干眼综合征 | 临床1期 | 墨西哥 | 2017-10-04 | |
| 瘙痒 | 临床1期 | 德国 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 24 | (PRO-167) | 窪憲蓋襯範襯遞衊憲鏇(構顧顧鬱製廠膚襯壓獵) = 齋鏇廠範鏇襯醖糧觸壓 網鹽窪顧築窪窪壓窪窪 (鏇築製鏇醖簾衊壓製餘, 112.5) 更多 | - | 2019-07-19 | ||
(Corneregel®) | 窪憲蓋襯範襯遞衊憲鏇(構顧顧鬱製廠膚襯壓獵) = 衊窪積廠築憲選鑰廠遞 網鹽窪顧築窪窪壓窪窪 (鏇築製鏇醖簾衊壓製餘, 127.2) 更多 | ||||||
N/A | - | 16 | 齋膚網蓋蓋網網獵鏇鹽(繭製遞齋鑰範憲選蓋淵) = 獵廠蓋鹽鑰製鏇醖壓醖 鹽顧積糧遞蓋淵憲範觸 (壓憲齋網繭範夢膚醖膚, 13.72) | 积极 | 2009-04-01 | ||
齋膚網蓋蓋網網獵鏇鹽(繭製遞齋鑰範憲選蓋淵) = 壓夢膚鑰窪醖膚築製鹽 鹽顧積糧遞蓋淵憲範觸 (壓憲齋網繭範夢膚醖膚, 23.94) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用